United Therapeutics (NASDAQ:UTHR) EVP Sells $4,010,975.00 in Stock

United Therapeutics Corporation (NASDAQ:UTHR) EVP Paul Mahon sold 8,300 shares of United Therapeutics stock in a transaction that occurred on Thursday, February 5th. The shares were sold at an average price of $483.25, for a total transaction of $4,010,975.00. Following the sale, the executive vice president owned 36,781 shares of the company’s stock, valued at approximately $17,774,418.25. The trade was a 18.41% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website.

United Therapeutics Price Performance

UTHR traded down $3.66 during midday trading on Thursday, reaching $478.93. 432,764 shares of the company’s stock were exchanged, compared to its average volume of 359,356. United Therapeutics Corporation has a 1-year low of $266.98 and a 1-year high of $519.99. The business’s 50-day moving average price is $486.95 and its 200 day moving average price is $424.86. The stock has a market capitalization of $20.62 billion, a PE ratio of 18.15, a P/E/G ratio of 2.54 and a beta of 0.85.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently made changes to their positions in the company. CWM LLC lifted its holdings in United Therapeutics by 204.3% in the 2nd quarter. CWM LLC now owns 5,194 shares of the biotechnology company’s stock valued at $1,492,000 after acquiring an additional 3,487 shares during the last quarter. AXQ Capital LP boosted its stake in United Therapeutics by 495.4% in the 2nd quarter. AXQ Capital LP now owns 3,888 shares of the biotechnology company’s stock worth $1,117,000 after purchasing an additional 3,235 shares during the period. AE Wealth Management LLC grew its holdings in shares of United Therapeutics by 396.3% during the third quarter. AE Wealth Management LLC now owns 4,288 shares of the biotechnology company’s stock valued at $1,798,000 after buying an additional 3,424 shares in the last quarter. Great Lakes Advisors LLC grew its stake in United Therapeutics by 194.7% during the 3rd quarter. Great Lakes Advisors LLC now owns 4,503 shares of the biotechnology company’s stock valued at $1,888,000 after acquiring an additional 2,975 shares in the last quarter. Finally, Osaic Holdings Inc. lifted its position in United Therapeutics by 271.0% in the 2nd quarter. Osaic Holdings Inc. now owns 46,082 shares of the biotechnology company’s stock worth $14,027,000 after buying an additional 33,662 shares in the last quarter. 94.08% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

A number of research analysts recently weighed in on the company. HC Wainwright lifted their target price on United Therapeutics from $500.00 to $525.00 and gave the company a “buy” rating in a report on Thursday, October 30th. Royal Bank Of Canada upped their target price on shares of United Therapeutics from $569.00 to $587.00 and gave the company an “outperform” rating in a research note on Thursday, October 30th. Morgan Stanley set a $447.00 price target on United Therapeutics in a report on Wednesday, October 29th. UBS Group raised their price objective on shares of United Therapeutics from $600.00 to $645.00 and gave the stock a “buy” rating in a report on Tuesday, January 6th. Finally, Jefferies Financial Group reiterated a “buy” rating and issued a $575.00 target price on shares of United Therapeutics in a research report on Wednesday, November 19th. Eight research analysts have rated the stock with a Buy rating and three have given a Hold rating to the company. According to MarketBeat, United Therapeutics has an average rating of “Moderate Buy” and an average price target of $509.50.

About United Therapeutics

United Therapeutics Corporation (NASDAQ: UTHR) is a biotechnology company dedicated to the development and commercialization of unique products to address life-threatening illnesses. The company’s primary focus has been on pulmonary arterial hypertension (PAH), where it has launched several therapies designed to improve functional capacity and quality of life for patients. Its marketed products include continuous infusion treprostinil (Remodulin), inhaled treprostinil (Tyvaso), oral treprostinil (Orenitram) and tadalafil (Adcirca), each tailored to different modes of administration and patient needs.